JP2011037889A5 - - Google Patents

Download PDF

Info

Publication number
JP2011037889A5
JP2011037889A5 JP2010232130A JP2010232130A JP2011037889A5 JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5 JP 2010232130 A JP2010232130 A JP 2010232130A JP 2010232130 A JP2010232130 A JP 2010232130A JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5
Authority
JP
Japan
Prior art keywords
phospholipid
block copolymer
derived
amount
surface modifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010232130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011037889A (ja
JP5539839B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011037889A publication Critical patent/JP2011037889A/ja
Publication of JP2011037889A5 publication Critical patent/JP2011037889A5/ja
Application granted granted Critical
Publication of JP5539839B2 publication Critical patent/JP5539839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010232130A 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法 Expired - Fee Related JP5539839B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7980998P 1998-03-30 1998-03-30
US60/079,809 1998-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000540812A Division JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2011037889A JP2011037889A (ja) 2011-02-24
JP2011037889A5 true JP2011037889A5 (enExample) 2012-08-30
JP5539839B2 JP5539839B2 (ja) 2014-07-02

Family

ID=22152962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法
JP2010232130A Expired - Fee Related JP5539839B2 (ja) 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Country Status (14)

Country Link
US (1) US6387409B1 (enExample)
EP (1) EP1067914B1 (enExample)
JP (2) JP4709378B2 (enExample)
KR (1) KR100628341B1 (enExample)
CN (1) CN1303278B (enExample)
AT (1) ATE318132T1 (enExample)
AU (1) AU761205B2 (enExample)
CA (1) CA2326456C (enExample)
DE (1) DE69929959T2 (enExample)
ES (1) ES2257041T3 (enExample)
IL (3) IL162023A0 (enExample)
SE (1) SE0003429L (enExample)
TW (1) TWI267383B (enExample)
WO (1) WO1999049846A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
CA2326456C (en) * 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
JP5296954B2 (ja) * 1998-11-20 2013-09-25 オバン・エナジー・リミテッド 不溶性微粒子の安定なサスペンションを製造する方法
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CN100548271C (zh) 2004-01-20 2009-10-14 阿勒根公司 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
JPWO2006057429A1 (ja) * 2004-11-24 2008-06-05 ナノキャリア株式会社 ブロックコポリマーのモーフォロジーの変化方法
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
JP4879349B2 (ja) 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
US9492387B2 (en) 2010-10-29 2016-11-15 Western University Of Health Sciences Ternary mixture formulations
WO2014004507A1 (en) * 2012-06-27 2014-01-03 Shell Oil Company Fuel and engine oil composition and its use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
PT808154E (pt) * 1995-02-06 2001-06-29 Elan Pharma Int Ltd Formulacoes de compostos sob a forma de dispersoes em nanoparticulas em oleos ou acidos gordos digestiveis
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
CZ299790B6 (cs) * 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
AU1809499A (en) * 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
CA2326456C (en) * 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
KR20140029532A (ko) * 2011-09-30 2014-03-10 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 스퍼터링 타깃 및 그 제조 방법

Similar Documents

Publication Publication Date Title
JP2002509876A5 (enExample)
Salzano et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
JP2026035730A (ja) 免疫療法構築物およびその使用方法
JP2018188443A (ja) 癌を処置するための組成物および該組成物を製造するための方法
JP2014532665A5 (enExample)
JP7795461B2 (ja) ポリ乳酸塩を含む薬物送達用ナノ粒子組成物製造用キット
HRP20230655T1 (hr) Metode liječenja artritisa
HRP20251519T1 (hr) Liposomski pripravak i farmaceutski pripravak
JP2010512384A5 (enExample)
JP6893245B2 (ja) 脂質ナノ粒子用膜材料組成物
WO2014191569A1 (en) Pharmaceutical composition, preparation and uses thereof
CA2854430C (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
JPWO2020071349A1 (ja) 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
JP2022064923A (ja) 癌を治療するための方法および組成物
ES2645076T3 (es) Adyuvante
US20230310504A1 (en) Platelet membrane coated nanoparticles and uses thereof
TW202015703A (zh) 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
CA3150972A1 (en) Immune stimulating micelle composition
HRP20230985T1 (hr) Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi
Gonsalves et al. University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881 Email: jmenon@ uri. edu Tel: 401-874-4914
US20240358639A1 (en) Nanoparticles for cancer treatment
CN121263175A (zh) 吸入药物组合物
Liu Controlled Release of Therapeutic Agents from Polymeric Particles
JP4092367B1 (ja) リポソームおよびこれを含む免疫賦活活性用組成物。
WO2004087094A2 (en) Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance